BCIQ Profiles

Company Profile Report

Readout for Gilead’s remdesivir in COVID-19 could warrant emergency use authorization

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

Remdesivir is the new standard of care for COVID-19, NIAID director Anthony Fauci said Wednesday. Other treatments will be compared with Gilead’s antiviral, and the therapy will be combined with other investigational drugs including anti-inflammatory mAbs.

An Emergency Use Authorization from FDA to treat COVID-19 could be the next step for the Gilead Sciences Inc. (NASDAQ:GILD) antiviral, according to former FDA Commissioner Scott Gottlieb.

“Remdesivir is not a perfect drug and is likely to be used in narrow circumstances, probably for patients who require hospitalization and are at risk of bad outcomes because of other co-morbidities,” Gottlieb told BioCentury. “This is

Read the full 998 word article

How to gain access

Continue reading with a
two-week free trial.